Abstract 1260
Background
Most patients with advanced ovarian cancer, the eighth most common cause of cancer death in women worldwide, recur after they receive initial platinum-based chemotherapy. PARP inhibitors showed a synthetic lethality in cancer cells via specific DNA repair defects. Yet, the risk of secondary hematological malignancies (SHM) and hematological toxicities, remains substantial. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of SHM and hematological toxicities.
Methods
MEDLINE, EMBASE databases and meeting abstracts from inception through March 2018 were queried. Phase III RCTs that mention any hematological malignancies and toxicities as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) and absolute risk difference (RD) with 95% confidence interval (CI). Fixed effects model was applied.
Results
Three phase III RCTs with 1401 patients were eligible. The study arms used olaparib or niraparib or rucaparib while the control arms utilized placebo. The I2 statistic for heterogeneity was 16.86, and the heterogeneity X2 (Cochran’s Q) was 2 (P = 0.30), suggesting homogeneity. The SHM incidence was 12 (1.28%) in PARP inhibitors group vs 5 (1.07%) in control group. The RR for SHM was 1.14 (95% CI: 0.42 – 3.08, P = 0.79) and RD was 0.002 (95% CI: - 0.01 – 0.014, P = 0.72). The RR of all-grade side effects were as follows: anemia, 6.57 (95% CI: 4.64 – 9.30, p < 0.001); thrombocytopenia, 9.80 (95% CI: 6.19 – 15.50, p < 0.001); and neutropenia, 4.13 (95% CI: 2.79 – 6.12, p < 0.001). The RR of high-grade adverse effects were as follows: anemia, 28.85 (95% CI: 10.06 – 82.72, p < 0.001); thrombocytopenia, 28.74 (95% CI: 8.24 – 100.24, p < 0.001); and neutropenia, 5.90 (95% CI: 3.01 – 11.57, p < 0.001).
Conclusions
Patients on PARP inhibitors experienced a notable increase in the risk of all grades of hematological toxicities. However, there was no significant increase in the risk of secondary hematological malignancies in PARP inhibitors group. Long-term follow-up of these patients is required to determine the actual relation.
Clinical trial identification
Legal entity responsible for the study
Kyaw Zin Thein/ Texas Tech University Health Sciences Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract